Check for updates

OPEN ACCESS

EDITED BY Shi Zhou, Southern Cross University, Australia

REVIEWED BY Zhiwen Luo, Fudan University, China Yumei Han, Shanxi University, China

*CORRESPONDENCE Ming Hu, ☑ hming1122334455@gmail.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 18 March 2025 ACCEPTED 26 May 2025 PUBLISHED 13 June 2025

CITATION

Peng C, Hu M, Yang L and Yuan Z (2025) Effects of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) on cardiopulmonary function, body composition, and physical function in cancer survivors: a meta-analysis of randomized controlled trials.

Front. Physiol. 16:1594574. doi: 10.3389/fphys.2025.1594574

COPYRIGHT

© 2025 Peng, Hu, Yang and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Effects of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) on cardiopulmonary function, body composition, and physical function in cancer survivors: a meta-analysis of randomized controlled trials

Chenggen Peng^{1†}, Ming Hu²*, Linlin Yang^{3†} and Zhichao Yuan⁴

¹Hunan Agricultural University, Changsha, Hunan, China, ²Faculty of Sport and Health Sciences, Guangxi Science & Technology Normal University, Laibin, Guangxi, China, ³College of Sports, Hunan International Economics University, Changsha, Hunan, China, ⁴School of Sports Science, Changsha Normal University, Changsha, Hunan, China

Background: Advances in cancer treatment have led to a significant increase in the global number of cancer survivors. However, long-term health management challenges—such as reduced cardiopulmonary function, cancer-related fatigue, and metabolic dysregulation—remain formidable. The purpose of this study was to conduct a meta-analysis of randomized controlled trials (RCTs) to comprehensively compare the effects of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) on Cardiopulmonary function, body composition, and physical function in cancer survivors. Thereby providing evidence-based guidance for individualized exercise prescriptions.

Methods: By the PRISMA guidelines, we systematically searched databases including PubMed, Web of Science, Scopus, Embase, the Cochrane Library, and EBSCOhost up to February 2025. A total of 12 eligible RCTs were included, breast cancer (n = 7), colorectal cancer (n = 3), and mixed cancer types (n = 2). Meta-analysis was performed using Cochrane Collaboration's Review Manager 5.4, while sensitivity analyses were conducted with Stata MP 14.0 to assess the stability and reliability of the results. Egger's test was utilized to evaluate the presence of publication bias.

Results: The meta-analysis revealed that, compared with MICT, HIIT was significantly more effective in improving VO₂ peak (Peak Oxygen Uptake) in cancer survivors [SMD = 0.53, 95% CI (0.21, 0.84), Z = 3.30, P = 0.001]. However, no statistically significant differences were found between HIIT and MICT in terms of body composition (including Body Mass, Total Fat Mass, Lean Body Mass, Fat Percentage, Body Mass Index, Waist Circumference, and Hip

Circumference) or physical function (including Sit-to-Stand Test and 6-Minute Walk Test).

Conclusion: HIIT appears superior to MICT in enhancing VO_2 peak and, consequently, cardiopulmonary function in cancer survivors. Nonetheless, both training modalities yield comparable outcomes in body composition and physical function. Given the variability in the quantity and quality of the included studies, further well-designed and objective RCTs are warranted to validate these findings.

Systematic Review registration: https://www.crd.york.ac.uk/PROSPERO/ myprospero, identifier CRD420250654968.

KEYWORDS

HIIT, MICT, cancer survivors, cardiopulmonary function, body composition, physical function, meta-analysis

1 Introduction

Cancer is a group of diseases characterized by abnormal cell growth. It has become a major social, public health, and economic issue in the 21st century, and is one of the deadliest diseases worldwide, claiming millions of lives each year (Matthews et al., 2022). Statistics indicate that approximately one in five men or women will develop cancer during their lifetime, with about one in nine men and one in every twelve women succumbing to the disease (Bray et al., 2024; Xiong et al., 2024). However, with advances in early cancer screening and treatment techniques, the global number of cancer survivors has increased significantly (Costa et al., 2020; He et al., 2024). Cancer survivors are defined as individuals who survive during or after cancer treatment (Denlinger and Barsevick, 2009; Denlinger et al., 2014). Although the number of cancer survivors continues to rise and the quality of care has improved markedly, these individuals may still experience severe complications, cancer recurrence-associated mortality, and treatment-related adverse events (Chen et al., 2024). The primary treatment modalities for cancer survivors include surgery, chemotherapy, radiotherapy, and immunotherapy. However, these treatments are often accompanied by severe side effects, such as reduced cardiopulmonary function, muscle atrophy, fatigue syndrome, and psychological disorders, which significantly impair the long-term quality of life (Jereczek-Fossa et al., 2002; von Kemp and Cosyns, 2023).

Conventional cancer treatments mainly cover radiotherapy, surgery, and chemotherapy. Although a wide range of chemotherapeutic agents exist, their effectiveness is limited by several factors (Xu et al., 2023; Xu et al., 2024). Therefore, Mokashi et al. researched and explored novel phytonutrients and herbal materials as potential treatments based on Ayurvedic medicine (Mokashi and Bhatia, 2024). Zhang developed an image recognition program using AI techniques that was able to extract implicit information from a human face and effectively differentiate between a cancer patient and a healthy individual. The study revealed that the physiological basis of the AI observer lies in the close link between craniofacial genes and cancer susceptibility genes (Zhang et al., 2022). Guo et al. proposed that physical stimulation modulates the tumor microenvironment by altering the tumor vasculature system, remodeling the extracellular matrix, and activating the immune response, to achieve the goal of adjuvant to other tumor therapies (Guo et al., 2024). Additionally, a study by Luo et al. noted that leisure-time physical activity, defined as non-specific physical activity with an intensity of three or more metabolic equivalents across a range of activities, significantly reduces cancer risk and delays progression in patients (Luo et al., 2024).

Some studies have indicated that exercise, as a nonpharmacological intervention, has profound effects on improving chronic diseases related to metabolic syndrome, cardiovascular and pulmonary disorders, musculoskeletal and joint conditions, as well as cancer (Pedersen and Saltin, 2006; Mitchell and Barlow, 2011). Moreover, exercise interventions have been shown to effectively enhance the physiological function of cancer survivors, alleviate treatment-related toxicities, and reduce the risk of recurrence (Daum et al., 2016; Furmaniak et al., 2016; Schmitt et al., 2016; Cramer et al., 2017; Mustian et al., 2017; Hilfiker et al., 2018; Nakano et al., 2018; Yang et al., 2020) Previous research has demonstrated that physical activity can significantly increase peak oxygen uptake (VO_2 peak) in cancer survivors (Lee et al., 2019; Foulkes et al., 2023).

For most cancer survivors, lack of time and difficulties in maintaining regular exercise are common barriers to participation (Elshahat et al., 2021; Cariolou et al., 2023). High-intensity interval training (HIIT), as a structured and enhanced form of interval training involving short bouts of high-intensity exercise, is a time efficient approach (Weston et al., 2014; Batacan et al., 2017). HIIT fits the current situation of cancer survivors' lack of time due to its time efficiency, which may be one of the reasons for its high adherence, e.g., Isanejad et al. reported that exercise adherence in the HIIT group was superior to that of the MICT group (participation rate: 98% vs. 92%) (Isanejad et al., 2023). Dolan et al. showed that the adherence rate in the HIIT group was 100% compared to approximately 91.67% in the MICT group (Dolan et al., 2016). Additionally, Devin et al. noted that the

Abbreviations: RCTs, randomized controlled trials; HIIT, high-intensity interval training; MICT, moderate-intensity continuous training; VO_2 peak, peak oxygen uptake; SMD, standardized mean difference; BMI, body mass index; STS, sit-to-stand test; 6MWT, 6-minute walk test.

intervention completion rates for the HIIT and MICT groups were 94.7% and 89.5%, respectively (Devin et al., 2018). In addition, studies have shown that HIIT is more enjoyable than low or moderate-intensity aerobic exercise, and this enjoyment enhances participants' motivation to exercise, which in turn has a positive impact on compliance (Bartlett et al., 2011; Gillen and Gibala, 2014; Thum et al., 2017). Bartlett et al. showed higher ratings of postexercise perceived enjoyment after interval running compared to continuous running (p < 0.05) (Bartlett et al., 2011). Although some studies have shown higher adherence to HIIT, the results of these studies may be confounded by several factors, such as the study by Hooshmand Moghadam et al. which showed that the adherence rate in both the HIIT group and the MICT group was approximately 86.67% (Hooshmand Moghadam et al., 2021). Therefore, the results of the study need to be interpreted with caution as exercise adherence in cancer patients is influenced by multidimensional factors such as exercise intensity, psychological support, and individual health status.

Some evidence suggests that HIIT is associated with more pronounced improvements in VO2 peak and certain metabolic parameters while requiring less time compared to MICT (Gibala et al., 2014). However, other studies have indicated that HIIT does not result in greater enhancements in VO₂ peak than MICT (Bell et al., 2021). The differences between HIIT and MICT in terms of cardiopulmonary health and vascular function appear to be minimal (Weston et al., 2014; Milanović et al., 2015; Ramos et al., 2015). One meta-analysis found no significant difference in VO_2 peak between HIIT (n = 56) and MICT (n = 43) (p = 0.15) (Wallen et al., 2020). Moreover, there is a paucity of meta-analyses comparing the effects of HIIT and MICT in cancer survivors. Therefore, the primary objective of this systematic review and meta-analysis was to evaluate the effects of HIIT versus MICT in cancer survivors, with VO2 peak as the primary outcome and body composition and physical function as secondary outcomes.

2 Methods

This systematic review was registered with the International Prospective Register of Systematic Reviews (registration number: CRD420250654968). This systematic review and meta-analysis were conducted by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines.

2.1 Search strategy

A comprehensive search was conducted in databases including PubMed, Web of Science, Scopus, Embase, the Cochrane Library, and EBSCOhost, covering the period from their inception to February 2025. The search was limited to articles published in English. Reference management was performed using EndNote (version X9). In addition to investigating the effects of HIIT and MICT on cancer survivors, reference tracking was also conducted for previously published trials and meta-analyses in this field.

The search strategy involved the use of Medical Subject Headings (MeSH terms), including "Cancer Survivors," "High-Intensity Interval Training," and "Randomized Controlled Trial," as well as their free-text equivalents. Non-MeSH terms such as "Moderate-Intensity Continuous Training" and their synonyms were also employed, combined using Boolean operators. The article search was primarily conducted by two authors, HM and YLL. In cases of disagreement, a third author, PCG, was consulted to reach a consensus. All analyses were based on previously published studies; therefore, neither ethical approval nor informed consent from patients was required (Supplementary Table S1).

2.2 Inclusion and exclusion criteria

2.2.1 Inclusion criteria

- (1) Language: Studies published in English only.
- (2) Participants: Adult cancer survivors.
- (3) HIIT Group: Supervised or unsupervised HIIT (clearly defined high-intensity interval protocols, such as 80%–95% of maximum heart rate).
- (4) MICT Group: Supervised or unsupervised MICT (moderateintensity continuous training, such as 50%–70% of maximum heart rate).
- (5) Outcomes: Cardiovascular function, body composition, and physical function.
- (6) Study Design: Randomized controlled trials (RCTs).

2.2.2 Exclusion criteria

- Non-randomized studies, animal experiments, or studies with mixed interventions that did not distinguish between HIIT and MICT.
- (2) Studies lacking quantitative results or relevant outcome measurements.
- (3) Studies with incomplete data or those for which the full text was unavailable.
- (4) Studies involving multimodal exercise interventions (such as HIIT combined with resistance training).

2.3 Data extraction

In the initial search, all references were imported into EndNote (version X9). After removing duplicates, studies unrelated to the topic were excluded based on their titles. Further screening was conducted by reviewing abstracts and full texts. The extracted information included basic details (author, publication year, country, cancer type, gender, age, and sample size) and study characteristics (type of intervention, intervention frequency, intervention measures, duration, intensity, and outcome measures). For all groups, the mean changes from baseline and the standard deviations (SDs) of these changes, as well as the number of participants at each assessment, were extracted. In case of missing ending data, priority was given to obtaining the original data by contacting the original authors, and if this was not possible, reasonable extrapolations were made from the available data. If there was a situation where key data were missing altogether and the data could not be obtained, the study was deleted. If variables were reported at multiple time points during the intervention,

only pre- and post-intervention time points were included. The primary outcome was VO₂peak, and the secondary outcomes were body composition and physical function. Data extraction and summary were performed by two authors (HM and YLL). In cases of disagreement, a third author (PCG) was consulted to reach a decision.

2.4 Risk of bias

The risk of bias for the included RCTs was assessed using the Cochrane Collaboration's Risk of Bias 2 tool (RoB 2; version 2). This tool evaluates potential bias across five domains: the randomization process, deviations from intended interventions, missing outcome data, measurement of outcomes, and selection of the reported results. A study was judged to have a "low risk of bias" if all domains were rated as low risk. If at least one domain was rated as "some concerns," the study was judged to have "some concerns." A study was considered to have a "high risk of bias" if at least one domain was rated as high risk or if \geq 3 domains were rated as "some concerns." The risk of bias was independently assessed by two researchers (PCG and YLL). Any disagreements were resolved through consensus or, if necessary, by consulting a third researcher (HM).

2.5 Data analysis

Meta-analysis was conducted using Review Manager 5.4 software provided by the Cochrane Collaboration. Statistical significance was defined as a p-value <0.05. Since all outcomes were continuous variables, the standardized mean difference (SMD) and 95% confidence intervals (95% CI) were calculated. Heterogeneity was assessed using the I² statistic. An I² > 50% was considered to indicate significant heterogeneity. A random-effects model was used when I² ≥ 50%, and a fixed-effects model was applied when I² < 50%. If heterogeneity was substantial (I² ≥ 50%), subgroup analysis or sensitivity analysis was performed to interpret the results. Differences between groups were considered not significant if the SMD overlapped with zero. Stata MP 14.0 software was used for sensitivity analysis to determine the stability and reliability of the results. Egger's test was employed to assess potential publication bias.

3 Results

3.1 Search outcomes

The initial search yielded 413 articles, including 12 from PubMed, 19 from Web of Science, 13 from Scopus, 10 from Embase, 12 from Cochrane Library, and 347 from EBSCOhost. After removing 35 duplicate studies using EndNote, 287 articles were excluded based on their titles. According to the inclusion and exclusion criteria, 56 articles were removed after the abstract screening. Full-text review led to the exclusion of 26 studies, including 8 due to inconsistent interventions, 3 for missing data, 8 that were abstract-only, 5 research reviews, and 2 due to inconsistencies in research subjects. Additionally, 23 articles were identified through website and citation searching. After reviewing and excluding duplicates and non-relevant studies, 3 articles were included in the meta-analysis. Ultimately, 12 studies met the eligibility criteria and were included in the analysis (Figure 1).

3.2 Characteristics of the studies

From 2015 to 2023, a total of 12 studies were included in the meta-analysis: 1 from New Zealand (Bell et al., 2021), 6 from Australia (Devin et al., 2016; Toohey et al., 2016; Devin et al., 2018; Toohey et al., 2018; Northey et al., 2019; Toohey et al., 2020), 1 from Canada (Dolan et al., 2016), 2 from Iran (Hooshmand Moghadam et al., 2021; Isanejad et al., 2023), 1 from the United States (Moraitis et al., 2023), and 1 from Germany (Schmitt et al., 2016). The sample sizes ranged from 7 to 47 participants, with ages varying between 39 and 75 years. Based on cancer types, 7 studies focused on breast cancer survivors (Dolan et al., 2016; Schmitt et al., 2016; Northey et al., 2019; Toohey et al., 2020; Bell et al., 2021; Hooshmand Moghadam et al., 2021; Isanejad et al., 2023), 3 studies targeted colorectal cancer survivors (Devin et al., 2016; Devin et al., 2018; Moraitis et al., 2023), and 2 studies included mixed types of cancer survivors (Toohey et al., 2016; Toohey et al., 2018). The exercise duration varied from 3 to 12 weeks, with a frequency of 2-5 days per week, predominantly 3 days per week. The duration of each session ranged from 10 to 75 min (Supplementary Table S2).

3.3 Risk of bias assessment

According to the assessment based on Cochrane RoB2, we found that 4 studies (Schmitt et al., 2016; Toohey et al., 2020; Bell et al., 2021; Isanejad et al., 2023) showed some concerns of bias, while 8 studies (Devin et al., 2016; Dolan et al., 2016; Toohey et al., 2016; Devin et al., 2018; Toohey et al., 2018; Northey et al., 2019; Hooshmand Moghadam et al., 2021; Moraitis et al., 2023) were at high risk of bias. In terms of "Bias arising from the randomization process", 8 studies (Devin et al., 2016; Dolan et al., 2016; Toohey et al., 2016; Devin et al., 2018; Toohey et al., 2018; Northey et al., 2019; Hooshmand Moghadam et al., 2021; Moraitis et al., 2023) presented some concerns due to the lack of clear descriptions of the randomization process and allocation concealment methods. For "Bias due to deviations from intended intervention", all studies (Devin et al., 2016; Dolan et al., 2016; Schmitt et al., 2016; Toohey et al., 2016; Devin et al., 2018; Toohey et al., 2018; Northey et al., 2019; Toohey et al., 2020; Bell et al., 2021; Hooshmand Moghadam et al., 2021; Isanejad et al., 2023; Moraitis et al., 2023) might have been subjected to performance bias as neither participants nor researchers implemented blinding. Regarding "Bias due to missing outcome data", 1 study (Moraitis et al., 2023) exhibited some concerns as the proportion of missing participants exceeded 10%. In "Bias in measurement of the outcome", 8 studies (Devin et al., 2016; Dolan et al., 2016; Schmitt et al., 2016; Toohey et al., 2016; Devin et al., 2018; Toohey et al., 2018; Northey et al., 2019; Bell et al., 2021) had some concerns mainly because it was unclear whether the outcome assessors were blinded to group allocation. Concerning "Bias in selection of the reported result", 3 studies (Dolan et al., 2016;



Devin et al., 2018; Isanejad et al., 2023) showed some concerns due to the absence of information on whether the study protocol was pre-registered (Supplementary Table S3).

3.4 Meta-analysis

3.4.1 Cardiopulmonary function

3.4.1.1 VO₂ peak

Since among the 12 studies, only 7 involved the analysis of VO₂ Peak, Therefore, Seven studies (Devin et al., 2016; Dolan et al., 2016; Devin et al., 2018; Northey et al., 2019; Bell et al., 2021; Hooshmand Moghadam et al., 2021; Isanejad et al., 2023) were included in the analysis of the effects of HIIT and MICT on VO₂ Peak in cancer survivors. Among these, 92 participants were assigned to the HIIT group and 78 participants to the MICT group. The analysis revealed a significant difference in VO₂ Peak between HIIT and MICT [SMD = 0.53, 95% CI (0.21, 0.84), Z = 3.30, P = 0.001], with no heterogeneity observed (I² = 0%). The effect of the HIIT group was significantly greater than that of the MICT group (Figure 2A).

3.4.1.2 Sensitivity analysis

Allows for the evaluation of the robustness and reliability of results by systematically removing individual studies to assess their impact on the overall findings. In the sensitivity analysis, we found that even after excluding individual studies, the effect of HIIT and MICT on VO₂ Peak in cancer survivors remained significant, and the

results of the original meta-analysis did not significantly change due to variations in the number of studies. This indicates the robustness of the results (Figure 2B).

3.4.1.3 Publication bias analysis

To assess publication bias, we performed Egger's linear regression test. The results showed a P-value of 0.75, which is greater than 0.5, indicating that there is no significant publication bias according to Egger's linear regression analysis.

3.4.1.4 Subgroup analysis

Five studies (Dolan et al., 2016; Northey et al., 2019; Bell et al., 2021; Hooshmand Moghadam et al., 2021; Isanejad et al., 2023) included breast cancer survivors, totaling 100 subjects. Results showed an improvement in VO₂ peak in the HIIT group [SMD = 0.39, 95% CI (-0.02, 0.79), Z = 1.88, P = 0.06], the difference did not reach significance and was lower than the overall effect (SMD = 0.53). 2 studies (Devin et al., 2016; Devin et al., 2018) included colorectal cancer survivors, a total of 70 subjects, and showed [SMD = 0.74, 95% CI (0.24, 0.84), Z = 2.91, P = 0.004] (Figure 2C).

3.4.1.5 Heart rate

Two studies (Toohey et al., 2020; Isanejad et al., 2023) were included in the analysis of the effects of HIIT and MICT on Heart Rate in cancer survivors. Among these, 16 participants were assigned to the HIIT group and 15 participants to the MICT group. The analysis found no significant difference in Heart Rate between HIIT



HIIT versus MCIT with Cardiopulmonary function (A) The forest plot of the VO_2 peak (B) Sensitivity analysis of the VO_2 peak (C) Subgroup analysis of the VO_2 peak (D) The forest plot of the Heart Rate (E) The forest plot of the Resting Heart Rate.

and MICT [SMD = -0.55, 95% CI (-1.27, 0.18), Z = 1.47, P = 0.14], with no heterogeneity observed (I² = 0%) (Figure 2D).

3.4.1.6 Resting Heart Rate

Three studies (Dolan et al., 2016; Toohey et al., 2016; Toohey et al., 2018) were included in the analysis of the effects of HIIT and MICT on Resting Heart Rate in cancer survivors. Among these, 44 participants were assigned to the HIIT group and 40 participants to the MICT group. The analysis found no significant difference in Resting Heart Rate between HIIT and MICT [SMD = -0.11, 95% CI (-0.53, 0.32), Z = 0.48, P = 0.63], with no heterogeneity observed (I² = 0%) (Figure 2E).

3.4.2 Body composition

3.4.2.1 Body mass

Nine studies (Devin et al., 2016; Dolan et al., 2016; Schmitt et al., 2016; Toohey et al., 2016; Toohey et al., 2018; Bell et al., 2021; Hooshmand Moghadam et al., 2021; Isanejad et al., 2023; Moraitis et al., 2023) were included in the analysis of the effects of HIIT and MICT on body mass in cancer survivors. Among these, 121 participants were assigned to the HIIT group and 107 participants to the MICT group. The analysis found no significant difference in body mass between HIIT and MICT [SMD = 0.11, 95% CI (-0.15, 0.38), Z = 0.84, P = 0.4], with low heterogeneity observed ($I^2 = 14\%$) (Figure 3A).

3.4.2.2 Total fat mass

Nine studies (Devin et al., 2016; Schmitt et al., 2016; Toohey et al., 2016; Devin et al., 2018; Toohey et al., 2018; Bell et al., 2021; Hooshmand Moghadam et al., 2021; Isanejad et al., 2023; Moraitis et al., 2023) were included in the analysis of the effects of HIIT and MICT on total fat mass in cancer survivors. Among these, 115 participants were assigned to the HIIT group and 109 participants to the MICT group. The analysis found no significant difference in total fat mass between HIIT and MICT [SMD = -0.36, 95% CI (-0.82, 0.1), Z = 1.52, P = 0.13], with high heterogeneity observed ($I^2 = 62\%$) (Figure 3B).

3.4.2.3 Lean body mass

Seven studies (Devin et al., 2016; Schmitt et al., 2016; Toohey et al., 2016; Devin et al., 2018; Toohey et al., 2018; Bell et al., 2021; Isanejad et al., 2023) were included in the analysis of the effects of HIIT and MICT on lean body mass in cancer survivors. Among these, 100 participants were assigned to the HIIT group and 91 participants to the MICT group. The analysis found no significant difference in lean body mass between HIIT and MICT [SMD = -0.03, 95% CI (-0.26, 0.31), Z = 0.18, P = 0.86], with no heterogeneity observed (I² = 0%) (Figure 3C).

3.4.2.4 Fat percentage

Five studies (Devin et al., 2016; Toohey et al., 2016; Toohey et al., 2018; Isanejad et al., 2023; Moraitis et al., 2023) were included in the analysis of the effects of HIIT and MICT on fat percentage in cancer survivors. Among these, 65 participants were assigned to the HIIT group and 58 participants to the MICT group. The analysis found no significant difference in fat percentage between HIIT and MICT [SMD = -0.17, 95% CI (-0.53, 0.19), Z = 0.94, P = 0.34], with no heterogeneity observed (I² = 0%) (Figure 3D).

3.4.2.5 Body mass index

Three studies (Bell et al., 2021; Isanejad et al., 2023; Moraitis et al., 2023) were included in the analysis of the effects of HIIT and MICT on BMI(Body Mass Index) in cancer survivors. Among these, 22 participants were assigned to the HIIT group and 25 participants to the MICT group. The analysis found no significant difference in BMI between HIIT and MICT [SMD = 0.02, 95% CI (-0.56, 0.6), Z = 0.07, P = 0.94], with no heterogeneity observed ($I^2 = 0\%$) (Figure 3E).

3.4.2.6 Waist circumference

Five studies (Dolan et al., 2016; Toohey et al., 2016; Toohey et al., 2018; Bell et al., 2021; Isanejad et al., 2023) were included in the analysis of the effects of HIIT and MICT on waist circumference in cancer survivors. Among these, 64 participants were assigned to the HIIT group and 60 participants to the MICT group. The analysis found no significant difference in waist circumference between HIIT and MICT [SMD = -0.02, 95% CI (-0.37, 0.34), Z = 0.09, P = 0.93], with no heterogeneity observed (I² = 0%) (Figure 3F).

3.4.2.7 Hip circumference

Four studies (Dolan et al., 2016; Toohey et al., 2016; Toohey et al., 2020; Isanejad et al., 2023) were included in the analysis of the effects of HIIT and MICT on hip circumference in cancer survivors. Among these, 54 participants were assigned to the HIIT group and 50 participants to the MICT group. The analysis found no significant difference in hip circumference between HIIT and MICT [SMD = 0.03, 95% CI (-0.36, 0.41), Z = 0.13, P = 0.89], with no heterogeneity observed ($I^2 = 0\%$) (Figure 3G).

3.4.3 Physical function

3.4.3.1 STS

Four studies (Toohey et al., 2016; Toohey et al., 2018; Isanejad et al., 2023; Moraitis et al., 2023) were included in the analysis of the effect of HIIT and MICT on the Sit-to-Stand (STS) test in cancer survivors. The HIIT group consisted of 44 participants, while the MICT group had 44 participants. The study found no significant difference in STS between HIIT and MICT [SMD = -0.01, 95% CI (-0.45, 0.43), Z = 0.04, P = 0.96], showing low heterogeneity (I² = 2%) (Figure 4A).

3.4.3.2 6MWT

Two studies (Toohey et al., 2016; Toohey et al., 2018) were included in the analysis of the effect of HIIT and MICT on the 6-Minute Walk Test (6MWT) in cancer survivors. The HIIT group consisted of 32 participants, while the MICT group had 29 participants. The study found no significant difference in 6MWT between HIIT and MICT [SMD = 0.32, 95% CI (-0.19, 0.84), Z = 1.23, P = 0.22], showing high heterogeneity ($I^2 = 74\%$) (Figure 4B).

4 Discussion

The primary objective of this systematic review and metaanalysis was to analyze the effect of HIIT and MICT on VO_2 peak in cancer survivors and evaluate which exercise modality is more effective. The secondary objective was to analyze the impact of HIIT

Churches and C. I.			T-/-!			T	W-1-1-	N/ Figure 1 0501	Std. mean Diff	erence
Study or Subgroup Bell 2021	Mean	18 1	<u>10tal</u>	wiean	SD 15.64	<u>10tal</u>	o 2%	0.06 L0.81.0.04	IV. Fixed, 95	
Devin 2015	-0.6	15.2	29	0.3	17.1	10	3.2% 19.0%	-0.06 [-0.67, 0.55]		
Dolan 2015	-0.67	1.9	12	-0.41	2.08	11	10.6%	-0.13 [-0.95, 0.69]		-
Isanejad 2023	-0.08	7.87	10	-0.54	11.35	10	9.2%	0.05 [-0.83, 0.92]		_
Moghadam 2021	0	0.79	13	-0.91	0.45	13	9.4%	1.37 [0.50, 2.24]		
Moraitis 2023	0.31	0.1	2	-0.29	1.96	5	2.6%	0.29 [-1.37, 1.94]		
Schmitt 2015	-0.4 1	14.25	13	0	13.6	13	12.0%	-0.03 [-0.80, 0.74]		
Toohey 2016	-0.01	8.83	8	-1.82	11.57	8	7.3%	0.17 [-0.82, 1.15]		
Toolley 2018	-0.1	11.55	24	'	14.01	21	20.0%	-0.08 [-0.87, 0.50]		
Total (95% CI)			121			107	100.0%	0.11 [-0.15, 0.38]	*	
Heterogeneity: Chi2 =	= 9.32, df =	8 (P =	0.32);	² = 14%						
Test for overall effect	t: Z = 0.84 ((P = 0.4	0)						HIIT (experimental) MI	CT [control]
(\mathbf{A})										
(21)										
	ŀ	HIIT		1	MICT		5	td. Mean Difference	Std. Mean Diff	erence
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 9	95% CI
Bell 2021 Devic 2015	-0.2	9.81	10	-1.2	13.41	10	11.2%	0.08 [-0.80, 0.96]		
Devin 2018	25.3	0.69	14	-0.2	0.63	15	12.2%	-1.03 [-1.81 -0.25]		
Isaneiad 2023	-0.21	5.87	10	-0.28	7.62	10	11.2%	0.01 [-0.87, 0.89]		-
Moghadam 2021	-0.81	0.36	13	-0.18	0.14	13	9.8%	-2.23 [-3.25, -1.22]		
Moraitis 2023	-0.23	0.57	2	0.34	1.88	5	5.5%	-0.28 [-1.94, 1.37]		
Schmitt 2015	-0.5	10.81	13	-1.4	10.89	13	12.3%	0.08 [-0.69, 0.85]		-
Toohey 2016	0.07	7.47	8	-1.6	9.59	8	10.1%	0.18 [-0.80, 1.17]		
Tooney 2018	-1.4	0.91	24	0.5	12.25	21	14.4%	-0.18 [-0.76, 0.41]		
Total (95% CI)			115			109	100.0%	-0.36 [-0.82. 0.10]	•	
Heterogeneity: Tau ² :	= 0.29; Chi ²	² = 21.0	7, df =	8 (P = 1	0.007):	1 ² = 62 ⁴	%	,,		<u> </u>
Test for overall effect	t: Z = 1.52 ((P = 0.1	3)		. ,				-4 -2 0 HIIT (experimental)	2 4 CT (controll
(D)			-						min texhemmentari Mit	
(B)										
	н	нит		м	ІСТ		St	d. Mean Difference	Std. Mean Diffe	erence
Study or Subgroup	Mean	SD 1	Total	Mean	SD T	otal \	Veight	IV. Fixed, 95% CI	IV. Fixed, 95	% CI
Bell 2021	0.1	8.01	10	0.1	6.25	10	10.6%	0.00 [-0.88, 0.88]		
Devin 2015	0.6	1.3	21	0.3	1.3	14	17.6%	0.23 [-0.45, 0.90]	-+-	
Devin 2018	45.6	0.87	14	45.6	0.9	15	15.3%	0.00 [-0.73, 0.73]		
Isanejad 2023	0.13	4.11	10	-0.26	5.91	10	10.6%	0.07 [-0.80, 0.95]		_
Toohev 2016	-0.06	4 4 9	8	-0.02	4.00	8	8.5%	-0.01 [-0.99, 0.97]		
Toohey 2018	0.3	6.84	24	0.5	6.52	21	23.7%	-0.03 [-0.62, 0.56]		_
,										
Total (95% CI)			100			91 1	00.0%	0.03 [-0.26, 0.31]	🕈	
Heterogeneity: Chi ² =	= 0.49, df =	= 6 (P =	1.00);	l ² = 0%					-2 -1 0	1 2
Test for overall effect	:t: Z = 0.18 ((P = 0.8	86)						HIIT [experimental] MIC	CT [control]
(\mathbf{C})										
(0)										
	F	нит		м	сті		St	d Mean Difference	Std. Mean Diffe	erence
Study or Subaroup	Mean	SD 1	Total	Mean	SD T	otal \	Veight	IV. Fixed. 95% CI	IV. Fixed. 95	% CI
Devin 2015	-1	7.66	21	-0.4	8.06	14	28.2%	-0.07 [-0.75, 0.60]		-
Isanejad 2023	-0.29	4.78	10	-0.08	6.16	10	16.8%	-0.04 [-0.91, 0.84]		
Moraitis 2023	-0.5	0.85	2	0.4	1.74	5	4.6%	-0.47 [-2.16, 1.21]		
Toohey 2016	-0.77	7.28	8	-0.05	7.53	8	13.4%	-0.09 [-1.07, 0.89]		
Toohey 2018	-1.1	7.85	24	1.4	8.46	21	37.1%	-0.30 [-0.89, 0.29]		
Total (95% CI)			65			58	00.0%	-0 17 [-0 53 0 10]	-	
Hotorogonoity: Chi2 -	-051 df-	- 4 (P -	0 071	12 - 0%		50	100.078	-0.17 [-0.00, 0.10]		
Test for overall effect	z = 0.51, ul = 0.94	(P = 0.3	34)	1 - 076					-2 -1 0	1 2
		(.,						HIIT [experimental] MIC	CT [control]
(D)										
	н	HIIT		М	ICT		St	d. Mean Difference	Std. Mean Diffe	erence
Study or Subgroup	Mean	SD 1	Total	Mean	SD T	otal \	Veight	IV, Fixed, 95% CI	IV, Fixed, 95	% CI
Bell 2021	0.1	5.65	10	-0.3	6.52	10	43.9%	0.06 [-0.81, 0.94]		
		2 4 4		0.05	E 02	10	13 8%			_
Isanejad 2023	-0.06	3.44	10	0.35	0.03	10	40.078	-0.09 [-0.97. 0.79]		
Isanejad 2023 Moraitis 2023	-0.06 0.11	0.04	10 2	-0.08	0.66	5	12.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92]		
Isanejad 2023 Moraitis 2023	-0.06 0.11	0.04	10 2	-0.08	0.66	5	43.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92]		
Isanejad 2023 Moraitis 2023 Total (95% CI)	-0.06 0.11	0.04	10 2 22	-0.08	0.66	5 25	43.0% 12.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60]		 -
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² =	-0.06 0.11 = 0.16. df =	0.04 = 2 (P =	10 2 22 0.92).	0.35 -0.08	0.66	5 25	12.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60]		 - !!
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect	-0.06 0.11 = 0.16, df =	0.04 = 2 (P = (P = 0.0	10 2 22 0.92); 94)	-0.08 -0.08	0.66	5 25	12.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60]	-2 -1 0	
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect	-0.06 0.11 = 0.16, df = t: Z = 0.07 (0.04 = 2 (P = (P = 0.9	10 2 22 0.92); 94)	0.35 -0.08 ² = 0%	0.66	5 25	12.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60]	-2 -1 0 HIIT [experimental] MIC	- - 1 2 T [control]
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect	-0.06 0.11 = 0.16, df = t: Z = 0.07 (0.04 = 2 (P = (P = 0.9	10 2 22 0.92); 94)	0.35 -0.08 ² = 0%	0.66	5 25	12.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60]	-2 -1 0 HIIT [experimental] MIC	- 1 2 CT [control]
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (E)	-0.06 0.11 = 0.16, df = t: Z = 0.07 (0.04 = 2 (P = (P = 0.9	10 2 22 0.92); 94)	0.35 -0.08 ² = 0%	0.66	5 25 1	12.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60]	-2 -1 0 HIIT [experimental] MIC	- 1 2 Control]
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (E)	-0.06 0.11 = 0.16, df = t: Z = 0.07 (0.04 = 2 (P = (P = 0.9	10 2 22 0.92); 94)	-0.08 ² = 0%	0.66	5 25	12.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60]	-2 -1 0 HIIT [experimental] MIC	- 1 2 1 2 T [control]
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (E)	-0.06 0.11 = 0.16, df = dt: Z = 0.07 (0.04 = 2 (P = (P = 0.9	10 2 22 0.92); 94)	-0.08 ² = 0%	0.66 MICT	5 25 1	12.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60]	-2 -1 0 HIIT [experimental] MIC	- 1 2 T [control]
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (E) Study or Subgroup Bell 2021	-0.06 0.11 = 0.16, df = tt: Z = 0.07 (<u>Hean</u>	0.04 = 2 (P = (P = 0.9 HIIT <u>SD</u>	10 2 22 0.92); 94) <u>Total</u>	0.35 -0.08 ² = 0%	0.66 WICT <u>SD</u>	25 1 Total	12.3% 100.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference <u>IV. Fixed, 95% CI</u>	-2 -1 0 HiT [experimental] MIC Std. Mean Diff	- 1 2 T [control]
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015	-0.06 0.11 = 0.16, df = t: Z = 0.07 (<u>Hean</u> -1.9 1 -2.16	0.04 = 2 (P = (P = 0.9 HIIT <u>SD</u> 14.82 2.9	10 2 22 0.92); 94) <u>Total</u> 10 12	0.35 -0.08 ² = 0% <u>Mean</u> -2.6 -2.51	MICT 13.03 2.5	5 25 10 10	12.3% 100.0% <u>Weight</u> 16.3% 18.7%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.6 0.941	-2 -1 0 HIIT [experimental] MIC	
Isanejad 2023 Moraitis 2023 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023	-0.06 0.11 = 0.16, df = t: Z = 0.07 (<u>Mean</u> -1.9 1 -2.16 0.5	0.04 = 2 (P = (P = 0.9 HIIT <u>SD</u> 14.82 2.9 7.03	10 2 22 0.92); 94) <u>Total</u> 10 12 10	0.35 -0.08 ² = 0% <u>Mean</u> -2.6 -2.51 -2.2	MICT 13.03 2.5 9.86	5 25 1 <u>Total</u> 10 11 10	12.3% 100.0% 100.0% 16.3% 18.7% 16.1%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.99, 0.94] 0.30 [-0.83, 1.18]	-2 -1 0 HIIT [experimental] MIC IV. Fixed, 95	- 1 2 TT [control] erence 5% CI
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² + Test for overall effect (E) Study or Subgroup. Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016	-0.06 0.11 = 0.16, df = t: Z = 0.07 (Hean -1.9 f -2.16 0.5 -2.62 f	0.04 = 2 (P = (P = 0.9 HIIT 14.82 2.9 7.03 11.61	10 2 22 0.92); 94) <u>Total</u> 10 12 10 8	0.35 -0.08 ² = 0% <u>Mean</u> -2.6 -2.51 -2.2 -6.55	MICT 13.03 2.5 9.86 11.75	5 25 10 10 11 10 8	12.3% 100.0% 100.0% 16.3% 18.7% 16.1% 12.9%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference <u>IV. Fixed, 95% CI</u> 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.68, 1.18]	-2 -1 0 HIIT [experimental] MIC IV. Fixed, 95	
Isanejad 2023 Moraitis 2023 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2018	-0.06 0.11 = 0.16, df = t: Z = 0.07 (H Mean -1.9 1 -2.16 0.5 -2.62 1 -5.4 1	 3.44 0.04 = 2 (P = (P = 0.9) HIIT <u>SD</u> 14.82 2.9 7.03 11.61 11.15 	10 2 0.92); 94) Total 10 12 10 8 24	0.35 -0.08 ² = 0% <u>Mean</u> -2.6 -2.51 -2.2 -6.55 -0.7	MICT 5.03 0.66 MICT 5D 13.03 2.5 9.86 11.75 13.2	5 25 10 10 11 10 8 21	12.3% 100.0% Weight 16.3% 18.7% 16.1% 12.9% 35.9%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.58, 1.18] 0.32 [-0.67, 1.31] 0.32 [-0.57, 0.21]	-2 -1 0 HIIT [experimental] MIC	- 1 2 T [control] erence
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneily: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Beil 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2018	-0.06 0.11 = 0.16, df = tt: Z = 0.07 (H Mean -1.9 1 -2.16 0.5 -2.62 1 -5.4 1	<pre>3.44 0.04 = 2 (P = (P = 0.9 HIIT</pre>	10 2 22 0.92); 94) Total 10 12 10 8 24	0.35 -0.08 ² = 0% <u>Mean</u> -2.6 -2.51 -2.2 -6.55 -0.7	MICT 13.03 2.5 9.86 11.75 13.2	5 25 10 11 10 8 21	40.0% 12.3% 100.0% Weight 16.3% 18.7% 16.3% 12.9% 35.9%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.89, 0.94] 0.30 [-0.88, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.37, 0.21]	-2 -1 0 HIIT [experimental] MIC V. Fixed, 95	- 1 2 T [control] erence
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (E) Study or Subgroup Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2018 Total (95% CI)	-0.06 0.11 = 0.16, df = t: Z = 0.07 (Hean -1.9 1 -2.16 0.5 -2.62 1 -5.4 1	<pre>3.44 0.04 = 2 (P = (P = 0.9 HIIT</pre>	10 2 22 0.92); 94) Total 10 12 10 8 24 64	0.35 -0.08 ² = 0% <u>Mean</u> -2.6 -2.55 -0.7	MICT SD 13.03 2.55 9.86 11.75 13.2	5 25 1 10 11 10 8 21 60	12.3% 100.0% Weight 16.3% 18.7% 16.1% 12.9% 35.9% 100.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] ttd. Mean Difference <u>IV. Fixed, 95% CI</u> 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34]	-2 -1 0 HIIT [experimental] MIC	
Isanejad 2023 Moraitis 2023 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2018 Total (95% Cl) Heterogeneity: Chi ²	-0.06 0.11 = 0.16, df = = 0.16, df = = 0.16, df = -1.9 f -2.16 0.5 -2.62 f -5.4 f = 2.53, df = = 2.53, df =	$3.44 \\ 0.04 \\ = 2 (P = 0.9 \\ (P = 0.9 \\ 14.82 \\ 2.9 \\ 7.03 \\ 11.61 \\ 11.15 \\ = 4 (P = 1) \\ (P = 1) \\ = 0 \\$	10 2 22 0.92); 94) Total 10 12 10 8 24 64 0.64); 2)	0.35 -0.08 ² = 0% <u>Mean</u> -2.6 -2.51 -2.2 -6.55 -0.7	MICT SD 13.03 2.55 9.86 11.75 13.2	Total 10 11 10 8 21 60	40.0% 12.3% 100.0% Weight 16.3% 18.7% 16.1% 12.9% 35.9% 100.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.58, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34]	-2 -1 0 HIIT [experimental] MIC Std. Mean Diff	
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2018 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect	-0.06 :: 0.11 = = 0.16, df = :t: Z = 0.07 (= 1.9 - -1.9 - 1 -2.16 0.5 -2.26 2 -5.4 1 = 2.53, df = :t: Z = 0.09 ((3.44 0.04 = 2 (P = (P = 0.9) HIIT SD 14.82 2.9 7.03 11.61 11.15 = 4 (P = 0.9) 	10 2 22 0.92); 94) Total 10 12 10 8 24 64 0.64); 13)	0.35 -0.08 ² = 0% <u>Mean</u> -2.6 -2.51 -2.2 -6.55 -0.7	MICT 5.03 0.66 MICT 13.03 2.5 9.86 11.75 13.2	Total 10 11 10 8 21 60	40.0% 12.3% 100.0% Weight 16.3% 18.7% 16.1% 12.9% 35.9% 100.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference <u>IV. Fixed, 95% CI</u> 0.05 [-0.38, 0.92] 0.12 [-0.99, 0.94] 0.30 [-0.58, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34]	-2 -1 0 HIIT [experimental] MIC	
Isanejad 2023 Moraitis 2023 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Tochey 2016 Toohey 2018 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E)	-0.06 :: 0.11 = = 0.16, df = = 0.16, df = t: Z = 0.07 (-1.9 = -2.16 0.5 -2.62 = -5.4 = = 2.53, df = = 2.53, df =	$\begin{array}{l} \text{HIIT} \\ \text{HIIT} \\ \text{SD} \\ 14.82 \\ 2.9 \\ 7.03 \\ 11.61 \\ 11.15 \\ 4 \ (\text{P}=0.9) \end{array}$	10 2 22 0.92); 94) Total 10 12 10 12 24 64 8 24 64 93)	0.35 -0.08 ² = 0% <u>Mean</u> -2.6 -2.51 -2.2 -6.55 -0.7	VIICT SD 13.03 2.5 9.86 11.75 13.2	Total 25 1 10 11 10 8 21 60	12.3% 12.3% 100.0% 100.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itid. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.58, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21]	-2 -1 0 HIIT [experimental] MIC	
Isanejad 2023 Moraitis 2023 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2018 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (F)	-0.06 :: 0.11 = = 0.16, df = = 0.16, df = :t: Z = 0.07 (-2.16 0.5 -2.62 1 -5.4 1 = 2.53, df = :t: Z = 0.09 (HIIT SD 7.03 11.61 11.15 4 (P = 0.9	10 2 22 0.92); 94) Total 10 12 10 8 24 64 64 (0.64); 3)	0.35 -0.08 2 = 0% 2 = 0% 2 = 0%	MICT <u>SD</u> 13.03 2.5 9.86 11.75 13.2	Total 10 11 10 8 21 60	5.0% 12.3% 100.0% 100.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.89, 0.94] 0.39 [-0.85, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34]	-2 -1 0 HIIT [experimental] MIC	erence
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2018 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (F)	-0.06 :: 0.11 = = 0.16, df = = 1.9 f -2.16 0.5 -2.26 f -5.4 f = 2.53, df = t; Z = 0.09 (f	HIIT 50 4 (P = 0.9 14.82 2.9 7.03 11.61 11.15 4 (P = 0.9 HIIT	10 2 22 0.92); 94) <u>Total</u> 10 12 10 8 24 64 64 (0.64); 3)	0.35 -0.08 2 = 0% 1 <u>Mean</u> -2.6 -2.51 -2.2 -6.55 -0.7 2 = 0%	MICT <u>SD</u> 13.03 2.5 9.86 11.75 13.2 ICT	Total 10 11 10 8 21 60	12.3% 100.0% Weight 16.3% 18.7% 16.1% 12.9% 35.9% 100.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.89, 0.94] 0.39 [-0.88, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34] d. Mean Difference	-2 -1 0 HIT [experimental] MIC V. Fixed, 92 -2 -1 0 HIT [experimental] MIC HIT [experimental] MIC	
Isanejad 2023 Moraitis 2023 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Tochey 2018 Tochey 2018 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (F) <u>Study or Subgroup</u>	-0.06 :: 0.11 = = 0.16, df = :t: Z = 0.07 (Mean - -1.9 = -2.16 0.5 -2.62 = -5.4 = = 2.53, df = :t: Z = 0.09 (Mean -	HIIT 5D 4 (P = 0.9 4 (P = 0.9 114.82 2.9 7.03 11.61 11.15 4 (P = 1.9 HIIT SD SD SD	10 2 22 0.92); 94) <u>Total</u> 10 12 10 8 24 64 0.64); 33) <u>Total</u>	0.35 -0.08 2 = 0% 2 = 0% -2.51 -2.2 -2.51 -2.2 -6.55 -0.7 2 = 0% Mean	MICT <u>SD</u> 13.03 2.5 9.86 11.75 13.2 ICT <u>SD</u>	Total 10 11 10 11 10 8 21 60 	40.0% 12.3% 100.0% Weight 16.3% 18.7% 16.1% 12.9% 35.9% 100.0% St Weight	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.58, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.37, 0.21] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed, 95% CI	-2 -1 0 HIIT [experimental] MIC V. Fixed, 95 -2 -1 0 HIIT [experimental] MIC Std. Mean Diff V. Fixed, 95 V. Fixed, 95	
Isanejad 2023 Moraitis 2023 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (F) <u>Study or Subgroup</u> Dolan 2015	-0.06 :: 0.11 = = 0.16, df = t: Z = 0.07 (Hean -1.9 f -2.16 0.5 -2.62 t -5.4 f = 2.53, df = t: Z = 0.09 (Hean -1.81	 3.44 0.04 = 2 (P = 0.9 (P = 0.9 14.82 2.9 11.61 11.15 4 (P = 1.9 4 (P = 0.9 HIIT SD 1 2.2 	10 2 22 0.92); 94) Total 10 12 10 12 10 8 24 64 64 0.64); 33)	0.35 -0.08 2 = 0% <u>Mean</u> -2.6 -2.51 -2.2 -6.55 -0.7 2 = 0% <u>Mean</u> -2.17	MICT <u>SD</u> 13.03 2.5 9.86 11.75 13.2 ICT <u>SD</u> 1 2.26	5 25 1 10 11 10 8 21 60	12.3% 12.3% 100.0% 100.0% 16.1% 16.1% 16.1% 12.9% 35.9% 100.0% St <u>Weight</u> 22.2%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.39 [-0.88, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed, 95% CI 0.16 [-0.66, 0.98]	-2 -1 0 HIIT [experimental] MIC V. Fixed, 95 -2 -1 0 HIIT [experimental] MIC HIIT [experimental] MIC Std. Mean Diff IV, Fixed, 95	
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Totale 95% CI) Heterogeneity: Chi ² = Test for overall effect (F) <u>Study or Subgroup</u> Dolan 2015 Isanejad 2023	-0.06 :: 0.11 = 0.16, df = : :: Z = 0.07 (Mean1.9 i -2.16 - 0.5 -2.62 i -5.4 i = 2.53, df = : : Z = 0.09 (i -1.8 i : Z = 0.09 (i -1.8 i -1.8 i -0.5 i	 3.44 0.04 = 2 (P = 0.1 (P = 0.1 III.1 III.1 III.1 (P = 0.9 HIIT SD 2.2 7.31 	10 2 22 0.92); 94) 10 8 24 64 0.64); 13) Total 12 12 12	0.35 -0.08 2 = 0% 1 Mean -2.6 -2.51 -2.2 -6.55 -0.7 2 = 0% 1 2 = 0% 1 2 = 0% 1 2 = 0%	VIICT SD 13.03 2.55 9.86 11.75 13.2 IICT SD 1 2.26 7.15	Total 10 10 11 10 8 21 60	Veight 12.3% 100.0% Weight 16.3% 18.7% 16.1% 12.9% 100.0% St Veight 100.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] ktd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed, 95% CI 0.16 [-0.66, 0.98] 0.21 [-0.67, 1.09]	-2 -1 0 HiIT [experimental] MIC V. Fixed, 95 HIIT [experimental] MIC HIIT [experimental] MIC Std. Mean Diff	
Isanejad 2023 Moraitis 2023 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (F) <u>Study or Subgroup</u> Dolan 2015 Isanejad 2023 Toohey 2016	-0.06 0.11 = 0.16, df = t: Z = 0.07 + Mean -1.9 -2.16 0.5 -2.62 - -5.4 = 2.53, df = = 2.53, df = - -1.81 0.5 -3.06	HIIT = 2 (P = 0.9) $HIIT = 14.82 = 2.9$ $7.03 = 11.61 = 1.15$ $4 (P = 0.9)$ $HIIT = 5D = 7.7.31$ $9.95 = 5.22$	10 2 22 0.92); 94) Total 10 8 24 64 64 64 64; 13) Total 12 10 8 24 64 64 133)	0.35 -0.08 2 = 0% <u>Mean</u> -2.6 -2.51 -2.2 -6.55 -0.7 2 = 0% <u>Mean</u> -2.11 -2.1 -2.1 -2.1 -2.5 -0.7	MICT <u>SD</u> 13.03 2.5 9.86 11.75 13.2 ICT <u>SD</u> 7.15 9.93	Total 10 11 10 11 10 8 21 60 5 5 11 10 8 21 60 5 5 5 10 10 11 10 8 21 10 10 11 10 10 11 10 10 11 10 10	Veight 12.3% 100.0% Weight 16.3% 18.7% 16.1% 35.9% 100.0% St Veight 22.2% 19.3%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.58, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed, 95% CI 0.16 [-0.66, 0.98] 0.21 [-0.67, 1.09] 0.29 [-0.70, 1.27]	-2 -1 0 HIIT [experimental] MIC V. Fixed, 95 HIIT [experimental] MIC HIIT [experimental] MIC V. Fixed, 95	
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (F) <u>Study or Subgroup</u> Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2016 Toohey 2016	-0.06 :: 0.11 = 0.16, df = : 1.2 = 0.07 (3.44 0.04 = 2 (P = 0.9 (P = 0.9 14.82 2.9 7.03 7.03 11.61 11.15 HIIT SD 2.2 7.31 9.95 10.4	10 2 22 0.92); 94) Total 10 12 10 24 64 64 64 64 12 13) Total 12 12 10 8 24 64 4 22 10 13 13 13 12 12 10 13 13 12 12 13 13 12 12 10 12 13 13 10 12 12 10 13 13 10 12 12 12 10 13 13 12 10 12 10 13 13 10 12 12 10 13 10 12 12 10 13 13 10 12 12 10 10 12 13 10 12 12 10 13 13 12 12 10 12 12 10 13 12 12 10 12 12 10 12 12 10 12 12 10 13 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 12 12 12 12 12 12 12 12	0.35 -0.08 2 = 0% -2.6 -2.51 -2.2 -0.7 2 = 0% Mean -2.17 -1.1 -6.07 -0.9	MICT <u>SD</u> 13.03 2.5 9.86 11.75 13.2 ICT <u>SD</u> 2.26 9.93 13.4	Total 10 11 10 11 10 8 21 60 	50.0% 12.3% 100.0% 100.0% 10.1% 18.7% 16.1% 18.7% 16.1% 12.9% 100.0% St 22.2% 19.3% 15.3% 43.2%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed. 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.88, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed. 95% CI 0.16 [-0.66, 0.98] 0.21 [-0.67, 1.27] -0.21 [-0.80, 0.37]	-2 -1 0 HIIT [experimental] MIC V. Fixed, 92 -2 -1 0 HIIT [experimental] MIC HIIT [experimental] MIC Std. Mean Diff	
Isanejad 2023 Moraitis 2023 Total (95% C1) Heterogeneity: Chi ² = Test for overall effect (E) Study or Subgroup Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2018 Total (95% C1) Heterogeneity: Chi ² = Test for overall effect (F) Study or Subgroup Dolan 2015 Isanejad 2023 Toohey 2018 Total 2023 Toohey 2018	-0.06 0.11 = 0.16, df = t: Z = 0.07 (+ -1.9 f -2.16 -2.62 f -5.4 f = 2.53, df = t: Z = 0.09 (-5.4 f = 2.53, df = -5.4 f -5.4 f -5.4 f -5.5 f -6.5 f -5.6 f	3.44 0.04 = 2 (P = (P = 0.9) HIIT SD 11.61 2.9 7.03 11.61 11.15 4 (P = 0.9) HIIT SD 2.2 7.31 9.95 10.4	10 2 22 0.92); 94) Total 10 12 10 12 10 8 24 64 0.64); 13) Total 12 10 8 24 54 54 54	0.35 -0.08 ² = 0% Mean -2.6 -2.51 -2.2 -0.7 ² = 0% Mean -2.17 -1.1 -6.07 -0.9	NICT SD 13.03 2.5 9.86 11.75 13.2 13.2 13.2 13.2 13.2	Total 10 11 10 11 10 8 21 60 5 5 5 5 5 5 5 5 5 5 5 5 5	5.5.% (00.0%)	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.58, 1.18] 0.32 [-0.67, 1.31] -0.38 [-0.97, 0.21] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed, 95% CI 0.16 [-0.66, 0.98] 0.21 [-0.67, 1.09] 0.29 [-0.70, 1.27] -0.29 [-0.70, 1.27] -0.21 [-0.87, 0.34]	-2 -1 0 HIIT [experimental] MIC V. Fixed, 95 HIIT [experimental] MIC HIIT [experimental] MIC Std. Mean Diff	
Isanejad 2023 Moraitis 2023 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2018 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (F) <u>Study or Subgroup</u> Dolan 2015 Isanejad 2023 Toohey 2016 Toohey 2016 Toohey 2016 Toohey 2016	-0.06 :: 0.11 = 0.16, df = = 0.16, df = = t: Z = 0.07 (+ -1.9 = 1 -2.16 = 0.5 - -2.62 = 1 -5.4 = = 2.53, df = = -3.5 = = 1.18 = 4f - = 1.18 = 4f -	HIIT SD (P = 0.9) 14.82 2.9 11.61 11.15 4 (P = 1.1) (P = 0.9) HIIT SD 2.2 7.31 9.95 10.4	10 2 22 0.92); 94) Total 10 12 10 8 24 64 64 64 64 12 10 8 24 64 12 10 8 24 64 0.64); 12 10 8 24 64 0.02); 7 10 12 12 10 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 10 12 12 10 10 12 12 10 12 10 12 12 10 12 12 10 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 12 12 10 10 12 12 10 10 12 12 10 10 12 12 10 10 12 12 10 10 12 10 10 12 10 10 12 10 10 12 10 10 12 10 10 12 10 10 12 10 10 12 10 10 12 10 10 12 10 10 12 10 10 10 10 10 10 10 10 10 10	0.35 -0.08 2 = 0% 1 -2.6 -2.51 -2.2 -6.55 -0.7 2 = 0% 1 -2.17 -1.1 -6.07 -0.9 2 = 0%	MICT <u>SD</u> 13.03 2.5 13.2 9.86 11.75 13.2 13.2 13.2 13.2 13.2 13.2 13.4	Total 10 10 11 10 8 21 60 	5.3% 00.0% Weight 16.3% 16.1% 16.1% 16.1% 12.9% 35.9% 100.0% St Weight 22.2% 103.% 103.% 103.%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itid. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.58, 1.18] 0.32 [-0.67, 1.31] -0.32 [-0.67, 1.31] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed, 95% CI 0.16 [-0.66, 0.98] 0.21 [-0.67, 1.09] 0.29 [-0.70, 1.27] -0.21 [-0.80, 0.37] 0.03 [-0.36, 0.41]	-2 -1 0 HIIT [experimental] MIC V. Fixed, 95 HIIT [experimental] MIC HIIT [experimental] MIC Std. Mean Diff	
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (E) <u>Study or Subgroup</u> Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2016 Total (95% CI) Heterogeneity: Chi ² = Toohey 2016 Toohey 2016	-0.06 :: 0.11 = 0.16, df = 1 : Z = 0.07 (-1.9 = 1 -2.16 = 0.5 -2.62 = 1 -5.4 = 1 -5.5 = 1 -5.5 = 1 -3.5 = 1.18, df = 1.5 =	HIIT SD (P = 0.9) (P = 0.9) 14.82 2.9 7.03 11.61 11.15 4 (P = 0.9) (P = 0.9) P 2.2 2.9 7.31 9.95 10.4 3 (P = 1) (P = 0.9) (P = 0.9	10 2 22 0.92); 94) Total 10 8 24 64 0.64); 13) Total 12 10 8 24 54 0.76); 88)	0.35 -0.08 2 = 0% 2 = 0% -2.6 -2.51 -2.2 -6.55 -0.7 2 = 0% Mean -2.17 -1.1 -6.07 -0.9 2 = 0%	MICT <u>SD</u> 13.03 2.5 9.86 9.86 11.75 13.2 13.2 13.2 13.2 13.2	Total 1 10 11 10 8 21 60 50 50 50	50.5% 12.3% 00.0% Weight 16.3% 12.9% 35.9% 100.0% Sti 12.9% 35.9% 100.0% Sti 13.3% 43.2% 00.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed. 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.88, 1.18] 0.32 [-0.67, 1.31] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed. 95% CI 0.16 [-0.66, 0.98] 0.21 [-0.67, 1.09] 0.21 [-0.67, 0.27] -0.21 [-0.80, 0.37] 0.03 [-0.36, 0.41]	-2 -1 0 HIIT [experimental] MIC V. Fixed, 92 -2 -1 0 HIIT [experimental] MIC V. Fixed, 92 -2 -1 0 HIIT [experimental] MIC Std. Mean Diff	
Isaneja 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Ch ² = Test for overall effect (E) Study or Subgroup. Bell 2021 Dolan 2015 Isanejad 2023 Tochey 2016 Tochey 2018 Total (95% CI) Heterogeneity: Ch ² = Test for overall effect (F) Study or Subgroup. Dolan 2015 Isanejad 2023 Tochey 2018 Total (95% CI) Heterogeneity: Ch ² = Total (95% CI)	-0.06 :: 0.11 = 0.16, df = t: Z = 0.07 (+ Mean -1.9 f -2.16 - 0.5 -2.62 f -5.4 f = 2.53, df = t: Z = 0.09 (+ Mean -1.81 0.5 -3.66 : -3.5 = 1.18, df = t: Z = 0.13 (HIIT SD (P = 0.9) (P = 0.9) 14.82 2.9 7.03 11.61 11.15 4 (P = 0.9) (P = 0.9) HIIT 2.2 7.31 9.95 10.4 = 3 (P = 0.1)	10 2 22 0.92); 94) Total 10 12 10 8 24 64 0.64); 13) Total 12 10 8 24 54 0.76); 89)	0.35 -0.08 2 = 0% 2 = 0% -2.6 -2.51 -2.2 -2.2 -6.55 -0.7 2 = 0% 2 = 0%	MICT SD 13.03 2.5 9.86 11.75 13.2 ICT SD T 2.26 9.86 11.75 13.2 13.2 13.2 13.2	Total 1 10 11 10 11 10 8 21 60 	5.3% 000.0% Weight 16.3% 16.3% 16.1% 16.1% 16.1% 16.1% 16.3% 100.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] ikid. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.12 [-0.69, 0.94] 0.30 [-0.88, 1.18] 0.32 [-0.67, 1.31] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed, 95% CI 0.16 [-0.66, 0.98] 0.21 [-0.67, 1.09] 0.29 [-0.70, 1.27] -0.21 [-0.80, 0.37] 0.03 [-0.36, 0.41]	-2 -1 0 HIIT [experimental] MIC V. Fixed, 95 HIIT [experimental] MIC Std. Mean Diff IV. Fixed, 95 HIIT [experimental] MIC	
Isanejad 2023 Moraitis 2023 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (E) Study or Subgroup, Bell 2021 Dolan 2015 Isanejad 2023 Toohey 2018 Total (95% CI) Heterogeneity: Chi ² = Toshey 2015 Isanejad 2023 Total (95% CI) Heterogeneity: Chi ² = Total (95% CI) Heterogeneity: Chi ² = Total (95% CI) Heterogeneity: Chi ² = Test for overall effect (G)	-0.06 :: 0.11 = 0.16, df = 1 = 0.16, df = 1 = 1.18, df = 1 = 2.53, df = 1 = 2.53, df = 1 = 2.53, df = 1 = 1.18, df = 1 = 1.18, df = 1 = 1.18, df = 1	HIIT SD (P = 0.9) (P = 0.9) (P = 0.9) (P = 0.9) (P = 0.9) HIIT SD (P = 0.9) (P = 0.	10 2 22 0.92); 94) Total 10 12 10 12 10 64 64 (33) Total 12 10 8 24 54 0.76); 89)	0.35 -0.08 2 = 0% 2 = 0%	MICT <u>SD</u> 13.03 2.5 9.86 11.75 13.2 13.2 9.86 11.75 13.2 13.2	Total 10 11 10 11 10 8 21 60	5.3% 00.0% Weight 16.3% 16.1% 12.9% 100.0% St Weight 22.2% 19.3% 15.3% 43.2% 00.0%	-0.09 [-0.97, 0.79] 0.27 [-1.38, 1.92] 0.02 [-0.56, 0.60] itd. Mean Difference IV. Fixed, 95% CI 0.05 [-0.83, 0.92] 0.30 [-0.58, 1.18] 0.32 [-0.67, 1.31] -0.32 [-0.67, 1.31] -0.02 [-0.37, 0.34] d. Mean Difference IV. Fixed, 95% CI 0.16 [-0.66, 0.88] 0.21 [-0.67, 1.09] 0.29 [-0.70, 1.27] -0.21 [-0.80, 0.37] 0.03 [-0.36, 0.41]	HIIT [experimental] MIC	

FIGURE 3 HIIT versus MCIT with Body composition (A) The forest plot of the Body mass (B) The forest plot of the Total fat mass (C) The forest plot of the Lean body mass (D) The forest plot of the Fat percentage (E) The forest plot of the Body Mass Index (F) The forest plot of the Waist circumference (G) The forest plot of the Hip circumference.



and MICT on body composition and physical function in cancer survivors. The results of this study showed that, compared to MICT, HIIT led to a statistically significant increase in VO₂ peak in cancer survivors. However, no statistically significant differences were found between HIIT and MICT in terms of body composition and physical function. It is important to note that the studies included in this meta-analysis focused on breast and colorectal cancer survivors, with only 2 studies including mixed cancer types. Although HIIT has shown significant benefits in improving VO₂ peak in breast and colorectal cancer patients, there may be differences in adaptations to high-intensity training in other cancer types due to physical status limitations.

Cardiopulmonary health, with VO_2 peak as the core indicator, is a key physiological measure in the rehabilitation process of cancer survivors. It is closely associated with their quality of life, treatment tolerance, recurrence risk, and long-term survival rates. Lower levels of VO_2 peak are linked to an increased cancer-specific mortality rate, making the enhancement of cardiopulmonary function a critical factor in reducing cancer-specific mortality. This emphasizes the importance of cardiopulmonary health in cancer survivors (Zhang et al., 2014; Lakoski et al., 2015; Schmid and Leitzmann, 2015).

Although this meta-analysis did not directly assess the effect of HIIT on cancer recurrence or survival, existing studies suggest that improvements in VO_2 peak may be strongly associated with mortality. For example, a cohort study by Lakoski et al. demonstrated a strong inverse association between cardiorespiratory fitness and colorectal cancer with a corrected hazard ratio (HR) of 0.56 (95% CI: 0.36–0.87) for colorectal cancer in men with high cardiorespiratory fitness compared with low cardiorespiratory fitness. High cardiorespiratory fitness reduced the risk of colorectal cancer by 44% compared to low cardiorespiratory fitness (Lakoski et al., 2015). In addition, a study by Kenfield

et al. found that physical activity was associated with lower cancer mortality among men with cancer. Men who performed \geq 3 h of vigorous activity per week had a 49% lower risk of all-cause mortality (HR, 0.51; 95% CI, 0.36–0.72) compared with shorter durations at an easy walking pace (Kenfield et al., 2011). Similarly, Zhang et al. found that maintaining or improving cardiorespiratory fitness may reduce the risk of cancer death. Loss of cardiorespiratory fitness was associated with an increased risk of premature death from cancer in men. In terms of public health messages, health and medical professionals should advise individuals to engage in regular physical activity to gain or maintain cardiorespiratory fitness (Zhang et al., 2014). Although these studies did not directly compare HIIT with MICT, their results support that high-intensity exercise may improve long-term prognosis through more efficient physiological adaptive mechanisms.

This study primarily found that HIIT improved cardiopulmonary health in cancer survivors compared to the MICT group. This finding is consistent with some research results. Several studies have shown that cancer survivors benefit more from HIIT than from MICT in terms of VO₂ peak improvement (Rognmo et al., 2004; Wisløff et al., 2007). For example, Isanejad's study found that MICT seemed to have no significant effect on VO2 peak, whereas HIIT was superior in improving VO₂ peak (mean difference = 2.974 mL/kg/min, 95% CI: -0.188 to 6.135, p = 0.005) (Isanejad et al., 2023). Devin's research showed that the absolute (p = 0.016) and relative (p = 0.021)mean changes in VO₂ peak in the HIIT group were significantly greater than in the MICT group (Devin et al., 2016). Billat et al. found that intermittent running with high-intensity components provided greater training stimuli compared to continuous running and might lead to more significant improvements in VO2 peak associated with oxygen consumption post-exercise (Billat et al., 2000).

However, there are also inconsistent findings. Mugele et al. concluded that when comparing HIIT to conventional treatments,

10.3389/fphys.2025.1594574

the intervention group showed an increase in VO₂ peak, but no significant difference was found between HIIT and MICT (Mugele et al., 2019). The BELL study found that HIIT did not lead to a greater VO₂ peak improvement than MICT; however, they encouraged future studies with higher intensity and frequency of training (Bell et al., 2021). The discrepancies between studies could be attributed to heterogeneity in the study populations (different cancer types, treatment stages, and comorbidities), variations in intervention protocols (different HIIT intensities, durations of intervals, and low-intensity or insufficient time in MICT), differences in adherence, and variations in measurement methods.

Based on the literature, it is hypothesized that the improvement of VO₂ peak by HIIT may be related to the following mechanisms: (1) HIIT activates the AMPK-PGC-1 α pathway and promotes the density and function of skeletal muscle mitochondria. Studies have shown that HIIT significantly increases AMPK phosphorylation and PGC-1a mRNA expression in skeletal muscle, promoting mitochondrial biosynthesis. For example, Broome et al. reported enhanced PGC-1a expression after HIIT, which correlated with increased peak power output, an indirect marker of increased peak VO₂ (Broome et al., 2022). This is supported by animal studies, which showed that the HIIT group was higher than the MICT group (P = 0.008), suggesting that HIIT significantly increased the expression of AMPK and PGC-1a more than MICT (Pirani et al., 2023). (2) Catecholamine-mediated cardiorespiratory adaptations. HIIT significantly increases plasma catecholamine (epinephrine and norepinephrine) levels during and after exercise, and these catecholamines have been associated with improved cardiovascular responses through β-adrenergic signaling. For example, Williams et al. demonstrated that exercise-induced catecholamine release enhances myocardial β-adrenergic receptor density, which may improve oxygen delivery and utilization during peak exercise (Williams et al., 1985). It should be clarified that the above mechanisms have not been directly verified in the present study.

We observed no statistically significant differences between HIIT and MICT in body composition (Body mass, Total fat mass, Lean body mass, Fat percentage, BMI, Waist circumference, and Hip circumference). Previous studies have indicated that exercise alone may not lead to weight loss, but preventing weight gain could be essential (Jakicic and Otto, 2005; Franz et al., 2007). In a randomized controlled trial, Isanejad et al. found no significant differences between the two groups in fat mass (p = 0.255), waist circumference (p = 0.397), hip circumference (p = 0.528), body weight (p = 0.613), and BMI (p = 0.497) after intervention (Isanejad et al., 2023). For measurements of lean body mass, fat mass, or fat percentage, no significant differences were observed between HIIT and MICT. However, while the HIIT group showed a greater average reduction in fat mass compared to the MICT group, the difference was not statistically significant (p = 0.060) (Devin et al., 2016).

We observed no significant differences between HIIT and MICT in physical function (STS, 6MWT). Consistent with our findings, Isanejad used the STS test to assess physical function and found no significant difference between the HIIT and MICT groups (p = 0.266) (Isanejad et al., 2023). However, Toohey's study found that participants in the HIIT group achieved a

greater effect in the STS test compared to the MICT group, suggesting improvements in lower limb strength (Toohey et al., 2016; Toohey et al., 2018). In the STS test, improvements were observed in both the HIIT group (20%) and the MICT group (9.5%), highlighting an increase in calf strength among those who completed the HIIT program. However, due to the small sample size, this difference was not statistically significant (Toohey et al., 2016). The lack of significant differences between HIIT and MICT in body composition and physical function in cancer survivors may stem from multiple factors such as energy expenditure balance, metabolic disturbances, insufficient intervention duration, and cancer-specific pathological mechanisms (Boutcher, 2011; Pedersen and Saltin, 2015; Graßmann et al., 2017; Maestroni et al., 2020).

This study systematically integrates RCTs and is the first comprehensive assessment of the effects of HIIT and MICT on cancer survivors' cardiopulmonary function (with VO2 peak as the core indicator), body composition, and physical function. The limitations of the study include: (1) the limited number of included studies and participants, which may lead to unreliable study results; (2) contains study heterogeneity, including inconsistencies in HIIT and MICT intervention protocols (including intensity, frequency vs. duration), cancer type, and other factors, as well as errors inherent in different measurement tools. The uneven distribution of cancer types in the study population, which was dominated by breast and colorectal cancers, may limit the applicability of the findings to other cancer subgroups; (3) potential publication bias and the lack of long-term follow-up data; (4) the inability to implement participant blinding due to the nature of the study type, making performance bias unavoidable in all trials; (5) the lack of subgroup analysis due to the limited number of studies, preventing understanding of the differences in effects across different populations, interventions, and durations; and (6) another limitation of this study is that survival or recurrence rates were not directly analyzed. Although VO2 peak is an independent predictor of cancer prognosis, its clinical translation still needs to be validated by randomized controlled trials (RCTs) with long-term follow-up.

Future research should aim to expand sample sizes, include subgroups of different cancer types, stages, and treatment phases, standardize interventions, and further optimize the precision and universality of exercise rehabilitation strategies for different cancer subtypes. Long-term follow-up should be established to track the effects of HIIT on cancer survivors' cardiopulmonary function and recurrence rates. Modern techniques such as remote monitoring and AI personalized prescriptions should be utilized to enhance the feasibility and clinical translational value of interventions.

5 Conclusion

This study found that for cancer survivors, HIIT appeared superior to MICT in enhancing VO_2 peak and, consequently, cardiopulmonary function in breast and colorectal cancer survivors. However, further studies are needed to validate its safety and efficacy in other cancer populations, particularly those with higher vulnerability to exercise-induced adverse events. There were no significant differences between the two training modes in terms of body composition and physical function indicators, which may be related to factors such as energy metabolism balance and insufficient intervention duration. It is important to note that the conclusions are based on a limited number of studies, and more research is needed in the future to explore the effects of HIIT and MICT on cancer survivors. This will help in more accurately exploring personalized exercise prescriptions and optimizing cancer rehabilitation outcomes.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

CP: Writing – original draft, Formal Analysis, Writing – review and editing, Methodology, Data curation, Conceptualization, Investigation. MH: Supervision, Writing – review and editing, Methodology, Conceptualization, Validation, Project administration. LY: Conceptualization, Writing – review and editing, Data curation, Writing – original draft. ZY: Methodology, Writing – review and editing, Conceptualization.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. Hunan Provincial Philosophy and Social Science Fund Project: Research on Folk Sports Helping Social Adaptation of Relocated Residents in the

References

Bartlett, J. D., Close, G. L., MacLaren, D. P., Gregson, W., Drust, B., and Morton, J. P. (2011). High-intensity interval running is perceived to be more enjoyable than moderate-intensity continuous exercise: implications for exercise adherence. *J. Sports Sci.* 29 (6), 547–553. doi:10.1080/02640414.2010.545427

Batacan, R. B., Jr., Duncan, M. J., Dalbo, V. J., Tucker, P. S., and Fenning, A. S. (2017). Effects of high-intensity interval training on cardiometabolic health: a systematic review and meta-analysis of intervention studies. *Br. J. Sports Med.* 51 (6), 494–503. doi:10.1136/bjsports-2015-095841

Bell, R. A., Baldi, J. C., and Jones, L. M. (2021). Additional cardiovascular fitness when progressing from moderate-to high-intensity exercise training in previously trained breast cancer survivors. *Support. Care Cancer* 29 (11), 6645–6650. doi:10.1007/s00520-021-06259-w

Billat, V. L., Slawinski, J., Bocquet, V., Demarle, A., Lafitte, L., Chassaing, P., et al. (2000). Intermittent runs at the velocity associated with maximal oxygen uptake enables subjects to remain at maximal oxygen uptake for a longer time than intense but submaximal runs. *Eur. J. Appl. Physiol.* 81 (3), 188–196. doi:10.1007/s004210050029

Boutcher, S. H. (2011). High-intensity intermittent exercise and fat loss. J. Obes. 2011, 868305. doi:10.1155/2011/868305

Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA A Cancer J. Clin.* 74 (3), 229–263. doi:10.3322/caac.21834

Broome, S. C., Pham, T., Braakhuis, A. J., Narang, R., Wang, H. W., Hickey, A. J. R., et al. (2022). MitoQ supplementation augments acute exercise-induced increases in muscle PGC1a mRNA and improves training-induced increases in peak power independent of mitochondrial content and function in untrained middle-aged men. *Redox Biol.* 53, 102341. doi:10.1016/j.redox.2022.102341

Context of Rural Revitalization (Number: 22YBA100) Hunan Provincial Sports Bureau project (Number: 2024KT0154).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2025. 1594574/full#supplementary-material

Cariolou, M., Abar, L., Aune, D., Balducci, K., Becerra-Tomás, N., Greenwood, D. C., et al. (2023). Postdiagnosis recreational physical activity and breast cancer prognosis: global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis. *Int. J. Cancer* 152 (4), 600–615. doi:10.1002/ijc.34324

Chen, K., Guan, H., Sun, M., Zhang, Y., Zhong, W., Guo, X., et al. (2024). Effects of physical activity on cardiotoxicity and cardio respiratory function in cancer survivors undergoing chemotherapy: a systematic review and meta-analysis. *Integr. Cancer Ther.* 23, 1176. doi:10.1177/15347354241291176

Costa, I., Bittar, C. S., Fonseca, S. M. R., Carolina, M. P. D E. S., Dos Santos Rehder, M. H. H., Rizk, S. I., et al. (2020). Brazilian cardio-oncology: the 10-year experience of the Instituto do Cancer do Estado de Sao Paulo. *BMC Cardiovasc. Disord.* 20 (1), 206. doi:10.1186/s12872-020-01471-8

Cramer, H., Lauche, R., Klose, P., Lange, S., Langhorst, J., and Dobos, G. J. (2017). Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. *Cochrane Database Syst. Rev.* 1 (1), Cd010802. doi:10.1002/14651858.CD010802.pub2

Daum, C. W., Cochrane, S. K., Fitzgerald, J. D., Johnson, L., and Buford, T. W. (2016). Exercise interventions for preserving physical function among cancer survivors in middle to late life. *J. Frailty Aging* 5 (4), 214–224. doi:10.14283/jfa. 2016.92

Denlinger, C. S., and Barsevick, A. M. (2009). The challenges of colorectal cancer survivorship. *J. Natl. Compr. Canc Netw.* 7 (8), 883–893. doi:10.6004/jnccn. 2009.0058

Denlinger, C. S., Carlson, R. W., Are, M., Baker, K. S., Davis, E., Edge, S. B., et al. (2014). Survivorship: introduction and definition. Clinical practice guidelines in oncology. *J. Natl. Compr. Canc. Netw.* 12 (1), 34–45. doi:10.6004/jnccn.2014. 0005

Devin, J. L., Jenkins, D. G., Sax, A. T., Hughes, G. I., Aitken, J. F., Chambers, S. K., et al. (2018). Cardiorespiratory fitness and body composition responses to different intensities and frequencies of exercise training in colorectal cancer survivors. *Clin. Colorectal Cancer* 17 (2), e269–e279. doi:10.1016/j.clcc.2018.01.004

Devin, J. L., Sax, A. T., Hughes, G. I., Jenkins, D. G., Aitken, J. F., Chambers, S. K., et al. (2016). The influence of high-intensity compared with moderate-intensity exercise training on cardiorespiratory fitness and body composition in colorectal cancer survivors: a randomised controlled trial. *J. Cancer Surviv.* 10 (3), 467–479. doi:10.1007/s11764-015-0490-7

Dolan, L. B., Campbell, K., Gelmon, K., Neil-Sztramko, S., Holmes, D., and McKenzie, D. C. (2016). Interval versus continuous aerobic exercise training in breast cancer survivors-a pilot RCT. *Support Care Cancer* 24 (1), 119–127. doi:10.1007/s00520-015-2749-y

Elshahat, S., Treanor, C., and Donnelly, M. (2021). Factors influencing physical activity participation among people living with or beyond cancer: a systematic scoping review. *Int. J. Behav. Nutr. Phys. Act.* 18 (1), 50. doi:10.1186/s12966-021-01116-9

Foulkes, S. J., Howden, E. J., Haykowsky, M. J., Antill, Y., Salim, A., Nightingale, S. S., et al. (2023). Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study. *Brexit Study*. 147 (7), 532–545. doi:10.1161/CIRCULATIONAHA.122.062814

Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., et al. (2007). Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. *J. Am. Diet. Assoc.* 107 (10), 1755–1767. doi:10.1016/j.jada.2007.07.017

Furmaniak, A. C., Menig, M., and Markes, M. H. (2016). Exercise for women receiving adjuvant therapy for breast cancer. *Cochrane Database Syst. Rev.* 9 (9), Cd005001. doi:10.1002/14651858.CD005001.pub3

Gibala, M. J., Gillen, J. B., and Percival, M. E. (2014). Physiological and health-related adaptations to low-volume interval training: influences of nutrition and sex. *Sports Med.* 44 (Suppl. 2), S127–S137. doi:10.1007/s40279-014-0259-6

Gillen, J. B., and Gibala, M. J. (2014). Is high-intensity interval training a timeefficient exercise strategy to improve health and fitness? *Appl. Physiol. Nutr. Metab.* 39 (3), 409–412. doi:10.1139/apnm-2013-0187

Graßmann, S., Wirsching, J., Eichelmann, F., and Aleksandrova, K. (2017). Association between peripheral adipokines and inflammation markers: a systematic review and meta-analysis. *Obes. (Silver Spring)* 25 (10), 1776–1785. doi:10.1002/oby.21945

Guo, Z., Saw, P. E., and Jon, S. (2024). Non-invasive physical stimulation to modulate the tumor microenvironment: unveiling a New frontier in cancer therapy. *Bio. Integr.* 5 (1), 1–14. doi:10.15212/bioi-2024-0012

He, S., Xia, C., Li, H., Cao, M., Yang, F., Yan, X., et al. (2024). Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors. *Sci. China Life Sci.* 67 (1), 122–131. doi:10.1007/s11427-023-2423-1

Hilfiker, R., Meichtry, A., Eicher, M., Nilsson Balfe, L., Knols, R. H., Verra, M. L., et al. (2018). Exercise and other non-pharmaceutical interventions for cancerrelated fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis. *Br. J. Sports Med.* 52 (10), 651–658. doi:10.1136/bjsports-2016-096422

Hooshmand Moghadam, B., Golestani, F., Bagheri, R., Cheraghloo, N., Eskandari, M., Wong, A., et al. (2021). The effects of high-intensity interval training vs. Moderateintensity continuous training on inflammatory markers, body composition, and physical fitness in overweight/obses survivors of breast cancer: a randomized controlled clinical trial. *Cancers (Basel)* 13 (17), 4386. doi:10.3390/cancers13174386

Isanejad, A., Nazari, S., Gharib, B., and Motlagh, A. G. (2023). Comparison of the effects of high-intensity interval and moderate-intensity continuous training on inflammatory markers, cardiorespiratory fitness, and quality of life in breast cancer patients. *J. Sport Health Sci.* 12 (6), 674–689. doi:10.1016/j.jshs.2023.07. 001

Jakicic, J. M., and Otto, A. D. (2005). Physical activity considerations for the treatment and prevention of obesity. *Am. J. Clin. Nutr.* 82 (1 Suppl. 1), 226S–229s. doi:10.1093/ajcn/82.1.226S

Jereczek-Fossa, B. A., Marsiglia, H. R., and Orecchia, R. (2002). Radiotherapy-related fatigue. Crit. Rev. Oncol. Hematol. 41 (3), 317–325. doi:10.1016/s1040-8428(01)00143-3

Kenfield, S. A., Stampfer, M. J., Giovannucci, E., and Chan, J. M. (2011). Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. *J. Clin. Oncol.* 29 (6), 726–732. doi:10.1200/jco.2010.31. 5226

Lakoski, S. G., Willis, B. L., Barlow, C. E., Leonard, D., Gao, A., Radford, N. B., et al. (2015). Midlife cardiorespiratory fitness, incident cancer, and survival after cancer in men: the cooper center longitudinal study. *JAMA Oncol.* 1 (2), 231–237. doi:10.1001/jamaoncol.2015.0226

Lee, K., Kang, I., Mack, W. J., Mortimer, J., Sattler, F., Salem, G., et al. (2019). Feasibility of high intensity interval training in patients with breast Cancer undergoing anthracycline chemotherapy: a randomized pilot trial. *BMC Cancer* 19 (1), 653. doi:10.1186/s12885-019-5887-7 Luo, Z., Mei, J., Wang, X., Wang, R., He, Z., Geffen, Y., et al. (2024). Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibitionorchestrated inflammatory tumor immune microenvironment. *Cell Rep.* 43 (9), 114697. doi:10.1016/j.celrep.2024.114697

Maestroni, L., Read, P., Bishop, C., and Turner, A. (2020). Strength and power training in rehabilitation: underpinning principles and practical strategies to return athletes to high performance. *Sports Med.* 50 (2), 239–252. doi:10.1007/s40279-019-01195-6

Matthews, H. K., Bertoli, C., and de Bruin, R. A. M. (2022). Cell cycle control in cancer. Nat. Rev. Mol. Cell Biol. 23 (1), 74-88. doi:10.1038/s41580-021-00404-3

Milanović, Z., Sporiš, G., and Weston, M. (2015). Effectiveness of high-intensity interval training (hit) and continuous endurance training for VO2max improvements: a systematic review and meta-analysis of controlled trials. *Sports Med.* 45 (10), 1469–1481. doi:10.1007/s40279-015-0365-0

Mitchell, T., and Barlow, C. E. (2011). Review of the role of exercise in improving quality of life in healthy individuals and in those with chronic diseases. *Curr. Sports Med. Rep.* 10 (4), 211–216. doi:10.1249/JSR.0b013e318223cc9e

Mokashi, A., and Bhatia, N. M. (2024). Integrated network ethnopharmacology, molecular docking, and ADMET analysis strategy for exploring the anti-breast cancer activity of ayurvedic botanicals targeting the progesterone receptor. *BIO Integr.* 5 (1). doi:10.15212/bioi-2024-0066

Moraitis, A. M., Rose, N. B., Johnson, A. F., Dunston, E. R., Garrido-Laguna, I., Hobson, P., et al. (2023). Feasibility and acceptability of an mHealth, home-based exercise intervention in colorectal cancer survivors: a pilot randomized controlled trial. *PLoS One* 18 (6), e0287152. doi:10.1371/journal.pone.0287152

Mugele, H., Freitag, N., Wilhelmi, J., Yang, Y., Cheng, S., Bloch, W., et al. (2019). Highintensity interval training in the therapy and aftercare of cancer patients: a systematic review with meta-analysis. *J. Cancer Surviv.* 13 (2), 205–223. doi:10.1007/s11764-019-00743-3

Mustian, K. M., Alfano, C. M., Heckler, C., Kleckner, A. S., Kleckner, I. R., Leach, C. R., et al. (2017). Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. *JAMA Oncol.* 3 (7), 961–968. doi:10.1001/jamaoncol.2016.6914

Nakano, J., Hashizume, K., Fukushima, T., Ueno, K., Matsuura, E., Ikio, Y., et al. (2018). Effects of aerobic and resistance exercises on physical symptoms in cancer patients: a meta-analysis. *Integr. Cancer Ther.* 17 (4), 1048–1058. doi:10.1177/1534735418807555

Northey, J. M., Pumpa, K. L., Quinlan, C., Ikin, A., Toohey, K., Smee, D. J., et al. (2019). Cognition in breast cancer survivors: a pilot study of interval and continuous exercise. J. Sci. Med. Sport 22 (5), 580–585. doi:10.1016/j.jsams.2018.11.026

Pedersen, B. K., and Saltin, B. (2006). Evidence for prescribing exercise as therapy in chronic disease. *Scand. J. Med. Sci. Sports* 16 (Suppl. 1), 3–63. doi:10.1111/j.1600-0838.2006.00520.x

Pedersen, B. K., and Saltin, B. (2015). Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. *Scand. J. Med. Sci. Sports* 25 (Suppl. 3), 1–72. doi:10.1111/sms.12581

Pirani, H., Bakhtiari, A., Amiri, B., and Salehi, O. R. (2023). Beneficial mitochondrial biogenesis in gastrocnemius muscle promoted by high-intensity interval training in elderly female rats. *Cell J.* 25 (1), 11–16. doi:10.22074/cellj.2022.557565.1078

Ramos, J. S., Dalleck, L. C., Tjonna, A. E., Beetham, K. S., and Coombes, J. S. (2015). The impact of high-intensity interval training versus moderate-intensity continuous training on vascular function: a systematic review and meta-analysis. *Sports Med.* 45 (5), 679–692. doi:10.1007/s40279-015-0321-z

Rognmo, Ø., Hetland, E., Helgerud, J., Hoff, J., and Slørdahl, S. A. (2004). High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease. *Eur. J. Cardiovasc. Prev. Rehabil.* 11 (3), 216–222. doi:10.1097/01.hjr.0000131677.96762.0c

Schmid, D., and Leitzmann, M. F. (2015). Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis. *Ann. Oncol.* 26 (2), 272–278. doi:10.1093/annonc/mdu250

Schmitt, J., Lindner, N., Reuss-Borst, M., Holmberg, H. C., and Sperlich, B. (2016). A 3-week multimodal intervention involving high-intensity interval training in female cancer survivors: a randomized controlled trial. *Physiol. Rep.* 4 (3), e12693. doi:10.14814/phy2.12693

Thum, J. S., Parsons, G., Whittle, T., and Astorino, T. A. (2017). High-intensity interval training elicits higher enjoyment than moderate intensity continuous exercise. *PLoS One* 12 (1), e0166299. doi:10.1371/journal.pone.0166299

Toohey, K., Pumpa, K., McKune, A., Cooke, J., DuBose, K. D., Yip, D., et al. (2018). Does low volume high-intensity interval training elicit superior benefits to continuous low to moderate-intensity training in cancer survivors? *World J. Clin. Oncol.* 9 (1), 1–12. doi:10.5306/wjco.v9.i1.1

Toohey, K., Pumpa, K., McKune, A., Cooke, J., Welvaert, M., Northey, J., et al. (2020). The impact of high-intensity interval training exercise on breast cancer survivors: a pilot study to explore fitness, cardiac regulation and biomarkers of the stress systems. *BMC Cancer* 20 (1), 787. doi:10.1186/s12885-020-07295-1

Toohey, K., Pumpa, K. L., Arnolda, L., Cooke, J., Yip, D., Craft, P. S., et al. (2016). A pilot study examining the effects of low-volume high-intensity interval training and

continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in cancer survivors. *PeerJ* 4, e2613. doi:10.7717/peerj.2613

von Kemp, B. A., and Cosyns, B. (2023). Radiation-induced pericardial disease: mechanisms, diagnosis, and treatment. *Curr. Cardiol. Rep.* 25 (10), 1113–1121. doi:10.1007/s11886-023-01933-3

Wallen, M. P., Hennessy, D., Brown, S., Evans, L., Rawstorn, J. C., Wong Shee, A., et al. (2020). High-intensity interval training improves cardiorespiratory fitness in cancer patients and survivors: a meta-analysis. *Eur. J. Cancer Care (Engl)* 29 (4), e13267. doi:10.1111/ecc.13267

Weston, K. S., Wisløff, U., and Coombes, J. S. (2014). High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. *Br. J. Sports Med.* 48 (16), 1227–1234. doi:10.1136/bjsports-2013-092576

Williams, M. E., Gervino, E. V., Rosa, R. M., Landsberg, L., Young, J. B., Silva, P., et al. (1985). Catecholamine modulation of rapid potassium shifts during exercise. *N. Engl. J. Med.* 312 (13), 823–827. doi:10.1056/nejm198503283121304

Wisloff, U., Støylen, A., Loennechen, J. P., Bruvold, M., Rognmo, Ø., Haram, P. M., et al. (2007). Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. *Circulation* 115 (24), 3086–3094. doi:10.1161/circulationaha.106.675041 Xiong, Z., Yuan, Y., Yang, Y., Qiu, B., Bai, Y., Wang, T., et al. (2024). Optimal exercise dose-response improves health-related quality of life in cancer survivors: a systematic review and Bayesian network metaanalysis of RCTs. *Front. Oncol.* 14, 1510578. doi:10.3389/fonc.2024. 1510578

Xu, H., Guo, Z., Li, M., Chaves, H. V., Pinto, V. D.P. T., Filho, G. C., et al. (2024). Copper-based nanomaterials for image-guided cancer therapy. *BIO Integr.* 5 (1), 1–14. doi:10.15212/bioi-2024-0013

Xu, Y., Zeng, Y., Xiao, X., Liu, H., Zhou, B., Luo, B., et al. (2023). Targeted imaging of tumor associated macrophages in breast cancer. *BIO Integr.* 4 (3). doi:10.15212/bioi-2022-0010

Yang, M., Liu, L., Gan, C. E., Qiu, L. H., Jiang, X. J., He, X. T., et al. (2020). Effects of home-based exercise on exercise capacity, symptoms, and quality of life in patients with lung cancer: a meta-analysis. *Eur. J. Oncol. Nurs.* 49, 101836. doi:10.1016/j.ejon.2020.101836

Zhang, H., Lv, G., Liu, S., Liu, D., and Wu, X.-Z. (2022). The artificial intelligence watcher predicts cancer risk by facial features. *Traditional Med. Res.* 7, 1. doi:10.53388/TMR20211227255

Zhang, P., Sui, X., Hand, G. A., Hébert, J. R., and Blair, S. N. (2014). Association of changes in fitness and body composition with cancer mortality in men. *Med. Sci. Sports Exerc.* 46 (7), 1366–1374. doi:10.1249/mss.0000000000225